Why the study?
The 2022 ACC/AHA/HFSA guideline provided updated recommendations, prompting a summary of key recommendations for managing HFrEF and their impact on daily practice.
This article provides a practical summary of the 2022 ACC/AHA/HFSA heart failure guidelines specifically focused on the management of HFrEF in daily practice.
The 2022 guideline from the American College of Cardiology, American Heart Association, and Heart Failure Society of America provides practical recommendations for preventing, diagnosing, and managing patients with heart failure. This article summarizes the most important of these recommendations, specifically for managing patients with heart failure with reduced ejection fraction (HFrEF), and how they should change daily practice.
No takes yet. Share an insight, caveat, or question.
M. Kittleson (2023) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Sacubitril-valsartan vs. Enalapril was evaluated on Cardiovascular death and heart failure hospitalization (HR 0.80, 95% CI 0.73-0.87, p=<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: